High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill
Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people lose weight in the mid-stage study,
A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with ...
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
On Sept. 16 Novo Nordisk (NYSE: NVO) and Korro Bio (NASDAQ: KRRO) announced that they'd be starting a new drug-development collaboration worth hundreds of millions of dollars, in an area that most ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...
Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo ...
Friday, shares of Novo Nordisk A/S (NVO) are sliding following the announcement of safety results of phase 2a clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback